George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director


George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board as Independent Non-Executive Director.

Dr Gittleson has extensive international experience as a pharmaceutical physician and enterprise leader. Prior to joining the Board of George Medicines, Dr Gittleson worked at global ASX-listed specialty biotechnology company CSL Behring, where she most recently held the role of Chief Medical Officer. During her 15-year tenure at the company, she held various senior roles in clinical research, medical safety, medical and patient-related ethics, strategic product development, planning and implementation across multiple therapeutic and rare disease areas.

Dr Gittleson has been a scientific speaker at multiple medical conferences and regulatory workshops (FDA and EMA), and a keynote speaker at Women in Pharma & Leadership conferences for women working for ASX200-listed companies in 2017, 2018, 2019 and 2021.

She is a qualified medical physician and holds a Bachelor of Science and a Bachelor of Medicine and Surgery from the University of Witwatersrand, Johannesburg, South Africa. She also holds an Australian Medical Council Qualification and is a graduate of the Australian Institute of Company Directors and Stanford University’s Company Directors Course.

Professor Stephen MacMahon, Chairman of George Medicines, said: “I am delighted to welcome Dr Gittleson to George Medicines at such an important time for our company as we progress Phase III development of GMRx2, our novel, proprietary triple low-dose combination pill intended as a first-line treatment for hypertension. Her wealth of experience, both as a physician and in management, will be invaluable as we pursue our mission of tackling non-communicable diseases, the world’s leading causes of death and disability.”

Dr Charmaine Gittleson, Non-Executive Director of George Medicines, said: “I am thrilled to be joining the Board of George Medicines. With its platform of single-pill combination therapies, George Medicines has the potential to transform the lives of millions of people around the world. I am looking forward to working with such an experienced management team to make their vision a reality.”